CATALYST PHARMACEUTICALS, INC.

CPRX

CATALYST PHARMACEUTICALS, INC.

CPRX

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2025-12-12Shares Purchased (TTM):0Shares Sold (TTM):301,699

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:100,701,827Shares Outstanding:122,254,171Institutional Ownership Pct.:82.37%

Earnings Market Reaction:

Filing Date:2026-05-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	756	709	690	653	581	518	442	376	310	138	121	179
Accounts Receivable Net Current	131	126	106	66	71	65	58	57	60	54	48	43
Inventory Net	35	37	28	19	20	20	20	18	20	16	9	11
Prepaid Expense And Other Assets Current	19	21	28	21	14	21	18	24	14	13	14	9
Assets Current	940	894	852	759	686	624	539	474	405	219	192	241
Operating Lease Right Of Use Asset	2	2	2	2	2	2	2	2	2	3	3	3
Property Plant And Equipment Net	1	1	1	1	1	1	1	1	1	1	1	1
Finite Lived Intangible Assets Net	122	132	129	138	147	157	166	175	185	194	167	176
Deferred Income Tax Assets Net	55	53	48	51	48	46	48	40	38	37	37	23
Equity Securities F V N I Noncurrent	27	23	19	21	24	22	15	13	15	16	13	-
Assets	1,148	1,104	1,052	972	909	851	772	706	647	470	413	444
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	7	11	9	6	11	17	12	7	10	15	5	4
Accrued Liabilities Current	125	136	120	107	100	104	94	85	69	61	53	48
Liabilities Current	132	147	129	113	112	121	105	92	80	76	58	53
Operating Lease Liability Noncurrent	2	2	2	3	3	3	3	3	3	3	3	3
Other Liabilities Noncurrent	0	0	0	0	0	0	3	2	3	3	4	13
Liabilities	135	150	131	116	115	124	111	98	85	82	65	69
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	489	480	473	462	452	442	432	423	417	266	262	258
Retained Earnings Accumulated Deficit	523	474	447	394	342	285	229	185	145	121	86	117
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	0	-0	0	0	0	0	0	0	0
Stockholders Equity	1,013	954	920	856	794	728	661	609	561	388	349	375
Liabilities And Stockholders Equity	1,148	1,104	1,052	972	909	851	772	706	647	470	413	444
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	200	200	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	122	123	123	122	122	121	119	119	118	107	107	107
Shares Outstanding	122	123	123	122	122	121	119	119	118	107	107	107

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	0.39%	0.96%	-	-	-	-	-	-	-	-	-	-
2025	6.39%	-7.16%	-10.61%	-5.51%	-10.42%	-3.81%	9.49%	13.89%	10.29%	-8.33%	5.63%	25.42%
2024	9.85%	5.23%	19.50%	24.77%	20.52%	32.22%	-2.82%	-5.46%	-0.70%	17.74%	9.43%	18.42%
2023	-	-	-	-1.42%	-17.21%	-14.94%	18.18%	34.05%	13.96%	8.04%	3.91%	13.26%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	7.10	6.08	6.62	6.71	6.14	5.17	5.11	5.14	5.09	2.88	3.32	4.59
Quick Ratio	6.70	5.68	6.19	6.36	5.84	4.83	4.75	4.69	4.66	2.51	2.92	4.22
Working Capital	807.99M	746.88M	723.72M	645.73M	574.07M	502.93M	433.60M	382.11M	325.04M	143.27M	134.21M	188.47M
Leverage & Debt
Debt to Equity	0.13	0.16	0.14	0.14	0.14	0.17	0.17	0.16	0.15	0.21	0.19	0.18
Debt Ratio	0.12	0.14	0.12	0.12	0.13	0.15	0.14	0.14	0.13	0.17	0.16	0.15
Efficiency & Turnover
Asset Turnover TTM	0.58	0.60	0.63	0.67	0.69	0.74	0.78	0.76	0.78	0.94	0.93	0.85
Days Sales Outstanding TTM	61.79	59.48	51.98	40.20	44.98	44.16	42.14	41.99	41.66	29.31	30.06	31.56
Receivables Turnover TTM	5.91	6.14	7.02	9.08	8.12	8.27	8.66	8.69	8.76	12.45	12.14	11.57
Per Share Metrics
Diluted EPS TTM	1.74	1.68	1.71	1.64	1.55	1.31	1.14	0.55	0.53	0.63	0.58	1.02
Free Cash Flow Per Share TTM	1.70	1.71	1.91	2.25	2.20	2.02	1.88	1.66	0.01	-0.18	-0.32	-0.36
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	85.96%	85.19%	85.68%	85.78%	86.11%	86.00%	86.32%	86.67%	86.74%	86.95%	86.41%	85.86%
Operating Profit Margin TTM	44.83%	43.77%	44.76%	43.58%	43.27%	39.68%	37.78%	19.77%	19.04%	21.80%	21.79%	45.62%
Net Profit Margin TTM	37.08%	36.39%	37.63%	37.36%	36.91%	33.33%	31.01%	15.69%	15.83%	17.93%	17.81%	38.14%
Growth Metrics
Net Revenue Growth (1Y)	11.65%	19.78%	25.56%	28.55%	29.97%	23.49%	32.17%	43.42%	60.38%	85.90%	81.69%	77.72%
Net Income Growth (1Y)	12.15%	30.78%	52.36%	206.19%	203.07%	129.50%	130.18%	-41.02%	-34.49%	-14.05%	-7.29%	112.02%
EPS Growth (1Y)	11.43%	26.68%	47.80%	196.21%	191.43%	105.91%	106.25%	-46.97%	-40.80%	-16.40%	-10.12%	105.11%
Calculated Values
Free Cash Flow TTM	208.13M	208.61M	234.54M	274.72M	267.57M	239.25M	224.02M	196.47M	806.00K	-18.92M	-34.40M	-38.17M
Net Debt	-755.86M	-709.17M	-689.89M	-652.80M	-580.66M	-517.55M	-442.33M	-375.69M	-310.41M	-137.64M	-120.97M	-178.79M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-12-12Sale

Owner: Harper, Molly

Title: -

Shares: 26,746

Price/Share: $23.33

Value: $623,984.18

Shares Owned: 2,360

Relationship: Director

Ownership: Direct

2025-11-26Sale

Owner: Del, Carmen Jeffrey

Title: Chief Commercial Officer

Shares: 10,983

Price/Share: $23.33

Value: $256,233.39

Shares Owned: 3,962

Relationship: Officer

Ownership: Direct

2025-11-12Sale

Owner: Elsbernd, Brian

Title: Chief Compliance/Legal Officer

Shares: 40,000

Price/Share: $22.70

Value: $908,000.00

Shares Owned: 231,039

Relationship: Officer

Ownership: Direct

2025-09-08Sale

Owner: Elsbernd, Brian

Title: Chief Compliance/Legal Officer

Shares: 30,000

Price/Share: $20.30

Value: $609,000.00

Shares Owned: 271,039

Relationship: Officer

Ownership: Direct

2025-09-04Sale

Owner: Elsbernd, Brian

Title: Chief Compliance/Legal Officer

Shares: 30,000

Price/Share: $19.52

Value: $585,600.00

Shares Owned: 188,564

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-12-12	Harper, Molly	Director	-	Direct	Sale	26,746	23.33	$623,984.18	2,360	4
2025-11-26	Del, Carmen Jeffrey	Officer	Chief Commercial Officer	Direct	Sale	10,983	23.33	$256,233.39	3,962	4
2025-11-12	Elsbernd, Brian	Officer	Chief Compliance/Legal Officer	Direct	Sale	40,000	22.70	$908,000.00	231,039	4
2025-09-08	Elsbernd, Brian	Officer	Chief Compliance/Legal Officer	Direct	Sale	30,000	20.30	$609,000.00	271,039	4
2025-09-04	Elsbernd, Brian	Officer	Chief Compliance/Legal Officer	Direct	Sale	30,000	19.52	$585,600.00	188,564	4
2025-08-27	Tierney, David S	Director	-	Direct	Sale	26,000	20.20	$525,200.00	379,620	4
2025-08-26	Daly, Richard J	Director,Officer	President and CEO	Direct	Sale	22,970	20.62	$473,641.40	226,794	4
2025-08-26	Miller, Steve	Officer	Chief Op. & Scientific Officer	Direct	Sale	115,000	20.28	$2,332,200.00	949,663	4
2025-06-11	Sundaram, Preethi	Officer	Chief Strategy Officer	Direct	Sale	1,600	26.42	$42,272.00	41,081	4
2025-06-09	Mcenany, Patrick J	Director,Other	-	Direct	Sale	171,748	26.11	$4,484,340.28	4,281,702	4
2025-05-30	Daly, Richard J	Director,Officer	President and CEO	Direct	Sale	70,000	24.86	$1,740,200.00	199,764	4
2025-05-14	Ingenito, Gary	Officer	Chief Med. & Reg. Officer	Direct	Sale	44,000	23.63	$1,039,720.00	68,873	4
2025-03-06	Ingenito, Gary	Officer	Chief Med. & Reg. Officer	Direct	Sale	180,096	21.67	$3,902,680.32	68,873	4
2025-03-03	Elsbernd, Brian	Officer	Chief Compliance/Legal Officer	Direct	Sale	62,975	23.08	$1,453,463.00	188,564	4
2025-03-03	Del, Carmen Jeffrey	Officer	Chief Commercial Officer	Direct	Sale	30,423	22.89	$696,382.47	0	4
2024-12-10	Miller, Steve	Officer	Chief Op. & Scientific Officer	Direct	Sale	50,000	21.93	$1,096,500.00	686,996	4
2024-11-27	Ingenito, Gary	Officer	Chief Med. & Reg. Officer	Direct	Sale	12,000	22.70	$272,400.00	51,391	4
2024-11-27	Harper, Molly	Director	-	Direct	Sale	17,500	22.00	$385,000.00	0	4
2024-11-26	Elsbernd, Brian	Officer	Chief Compliance/Legal Officer	Direct	Sale	13,256	21.62	$286,594.72	165,377	4
2024-11-20	Ingenito, Gary	Officer	Chief Med. & Reg. Officer	Direct	Sale	38,000	21.20	$805,600.00	51,391	4
2024-11-20	Mcenany, Patrick J	Director,Other	-	Direct	Sale	72,500	21.29	$1,543,525.00	4,478,169	4
2024-11-14	Mcenany, Patrick J	Director,Other	-	Direct	Sale	44,655	21.75	$971,246.25	4,478,169	4
2024-11-12	Mcenany, Patrick J	Director,Other	-	Direct	Sale	262,000	23.31	$6,107,220.00	4,478,169	4
2024-08-21	Tierney, David S	Director	-	Direct	Sale	15,000	20.10	$301,500.00	348,874	4
2024-08-20	Miller, Steve	Officer	Chief Op. & Scientific Officer	Direct	Sale	150,000	20.35	$3,052,500.00	675,124	4
2024-08-09	Del, Carmen Jeffrey	Officer	Chief Commercial Officer	Direct	Sale	36,058	18.43	$664,548.94	12,369	4
2024-08-09	Ingenito, Gary	Officer	Chief Med. & Reg. Officer	Direct	Sale	100,000	18.04	$1,804,000.00	51,391	4
2024-06-07	Del, Carmen Jeffrey	Officer	Chief Commercial Officer	Direct	Sale	7,541	16.07	$121,183.87	18,427	4
2024-06-05	Ingenito, Gary	Officer	Chief Med. & Reg. Officer	Direct	Sale	80,000	16.16	$1,292,800.00	51,391	4
2024-06-04	Daly, Richard J	Director,Officer	President and CEO	Direct	Sale	17,323	15.98	$276,821.54	234,824	4
2024-06-03	Harper, Molly	Director	-	Direct	Sale	5,333	16.30	$86,927.90	0	4
2024-04-08	Tierney, David S	Director	-	Direct	Sale	25,000	15.68	$392,000.00	348,874	4
2024-03-27	Elsbernd, Brian	Officer	Chief Compliance/Legal Officer	Direct	Sale	25,000	16.44	$411,000.00	124,433	4
2023-12-15	Harper, Molly	Director	-	Direct	Sale	14,000	14.40	$201,600.00	0	4
2023-12-12	Tierney, David S	Director	-	Direct	Sale	50,000	13.33	$666,500.00	333,541	4
2023-12-11	Grande, Alicia	Officer	VP, Treasurer and CFO	Direct	Sale	60,000	13.76	$825,600.00	50,557	4
2023-12-06	Ingenito, Gary	Officer	Chief Med. & Reg. Officer	Direct	Sale	50,000	14.02	$701,000.00	38,367	4
2023-12-05	Miller, Steve	Officer	Chief Op. & Scientific Officer	Direct	Sale	40,000	14.24	$569,600.00	647,457	4
2023-05-15	Mcenany, Patrick J	Director,Officer	President and CEO	Direct	Sale	26,151	13.23	$345,977.73	3,945,436	4
2023-04-05	Tierney, David S	Director	-	Direct	Sale	30,000	16.83	$504,900.00	313,541	4
2023-03-29	Grande, Alicia	Officer	VP, Treasurer and CFO	Direct	Sale	50,000	16.70	$835,000.00	50,557	4
2023-03-29	Del, Carmen Jeffrey	Officer	Chief Commercial Officer	Direct	Sale	40,000	16.70	$668,000.00	7,541	4
2023-03-22	Grande, Alicia	Officer	VP, Treasurer and CFO	Direct	Sale	41,784	16.46	$687,764.64	50,557	4
2023-03-20	Elsbernd, Brian	Officer	Chief Compliance/Legal Officer	Direct	Sale	50,000	16.07	$803,500.00	138,076	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

82.37%

Inst. Shares: 100,701,827

Shares Outstanding: 122,254,171

2025-12-31

82.56%

Inst. Shares: 100,959,390

Shares Outstanding: 122,290,866

2025-09-30

82.04%

Inst. Shares: 100,586,157

Shares Outstanding: 122,600,730

2025-06-30

80.07%

Inst. Shares: 97,813,368

Shares Outstanding: 122,163,212

2025-03-31

76.66%

Inst. Shares: 93,123,115

Shares Outstanding: 121,472,468

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	100,701,827	122,254,171	82.37%
2025-12-31	100,959,390	122,290,866	82.56%
2025-09-30	100,586,157	122,600,730	82.04%
2025-06-30	97,813,368	122,163,212	80.07%
2025-03-31	93,123,115	121,472,468	76.66%
2024-12-31	95,047,445	118,457,673	80.24%
2024-09-30	90,923,477	118,931,153	76.45%
2024-06-30	93,337,140	118,180,396	78.98%
2024-03-31	90,329,436	116,806,117	77.33%
2023-12-31	78,574,572	106,279,736	73.93%
2023-09-30	75,092,025	106,568,137	70.46%
2023-06-30	76,870,107	106,258,790	72.34%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

CATALYST PHARMACEUTICALS, INC. (CPRX) — SEC Financial Statements & Analysis

CATALYST PHARMACEUTICALS, INC. (CPRX) is a pharmaceutical preparations company, incorporated in DE. CATALYST PHARMACEUTICALS, INC. trades on Nasdaq as: CPRX. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), CATALYST PHARMACEUTICALS, INC. reported a 11.65% year-over-year revenue growth, a Gross Profit Margin of 85.96% (TTM), a Debt-to-Equity ratio of 0.13x. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 11.65%
Gross Profit Margin TTM: 85.96%
Debt To Equity: 0.13x

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is CATALYST PHARMACEUTICALS, INC. in?

CATALYST PHARMACEUTICALS, INC. (CPRX) operates in the Pharmaceutical Preparations industry.

What exchange does CPRX trade on?

CATALYST PHARMACEUTICALS, INC. (CPRX) trades on the Nasdaq.

Where is CATALYST PHARMACEUTICALS, INC. incorporated?

CATALYST PHARMACEUTICALS, INC. is incorporated in DE.